arrow_back Back to App

Tax Credits for Neurodegenerative and Psychiatric Research

This act introduces new tax credits for companies and organizations conducting research on neurodegenerative diseases and psychiatric conditions. The goal is to accelerate the development of new drugs and therapies, potentially improving the quality of life for those affected. Citizens may benefit from access to better treatment options in the future.
Key points
Businesses and organizations can receive a 25% tax credit for expenses related to neurodegenerative and psychiatric research.
The government will allocate billions of dollars for these credits from 2022-2028, prioritizing projects with high scientific merit.
Tax-exempt entities can transfer these credits to their eligible project partners, fostering collaboration.
The act aims to speed up the development of new therapeutics and devices for central nervous system disorders.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_7279
Sponsor: Rep. Thompson, Mike [D-CA-5]
Process start date: 2022-03-29
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Mental Health Research Accelerator Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7279.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-29.

What are the main provisions?

Key points include:

  • Businesses and organizations can receive a 25% tax credit for expenses related to neurodegenerative and psychiatric research.
  • The government will allocate billions of dollars for these credits from 2022-2028, prioritizing projects with high scientific merit.
  • Tax-exempt entities can transfer these credits to their eligible project partners, fostering collaboration.
  • The act aims to speed up the development of new therapeutics and devices for central nervous system disorders.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Thompson, Mike [D-CA-5].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Ways and Means.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Taxes Health